Immunotherapy resistance: The answers lie ahead - not in front - of us

Miles C. Andrews, Jennifer A. Wargo

Research output: Contribution to journalComment / DebateOtherpeer-review

10 Citations (Scopus)


Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manuscript by Zaretsky and colleagues, mutational events were identified that effectively crippled ongoing immunotherapy responses in patients treated with anti-PD-1 therapy. These results are discussed in the light of other recent and ongoing research efforts exploring both mutational and non-mutational resistance mechanisms, highlighting the critical translational importance of longitudinal tumor sampling.

Original languageEnglish
Article number10
Number of pages3
JournalJournal for ImmunoTherapy of Cancer
Issue number1
Publication statusPublished - 21 Feb 2017
Externally publishedYes


  • Checkpoint blockade
  • Interferon
  • Longitudinal biopsies
  • Resistance
  • T cell exclusion

Cite this